The collaboration supports efforts for HIV prevention through PrEP, emphasizing Hetero’s commitment to improving HIV care.

Fewer young people are having sex, but the teens and young adults who are sexually active aren't using condoms as regularly, ...

Condom usage is down for everyone in the U.S., but researchers say the trend is especially stark among teens and young adults ...

Gilead Sciences GILD has entered into licensing deals with six pharmaceutical companies to manufacture and supply a cheaper ...

Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

Indian pharmaceutical companies are set to produce generic versions of lenacapavir, an HIV prevention drug, under agreements ...

Schmid said although he's pleased about that surprise bonus, the transition to Part B is not without complications. "The ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

Condom usage is down among teens and young adults in the U.S. Medical advancements, a fading fear of contracting HIV and ...

The FDA has determined that the monoclonal antibody pemivibart (Pemgarda) is likely to be effective against currently ...

9–12 The safety and effectiveness of HIV pre-exposure prophylaxis (PrEP) has been shown in clinical trials and in ...